SLC5A2 and Hypoglycemia: Because SGLT2 inhibitors can lower blood sugar levels, a meta-analysis of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers combined with SGLT2 inhibitors in the treatment of diabetes found that combined therapy increased the risk of hypoglycemia (42).